Trial Profile
Randomized, Multicentre, Phase III Study: Assessment of the Duration of Androgen Blockade Combined With Pelvic Irradiation in High-Risk Prostate Cancers.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 20 May 2022 Planned End Date changed from 31 Dec 2025 to 31 Dec 2023.
- 20 May 2022 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2023.
- 07 Dec 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2025.